Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

By sjmartinez • January 14, 2025

Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 Jan 11:S0923-7534(25)00005-5. doi: 10.1016/j.annonc.2025.01.001. Epub ahead of print. PMID: 39805351.

Tags: Advanced NSCLC, antibody-drug conjugate, c-Met, Hematology/Oncology, Osimertinib, Publications, Teliso-V

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus

Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran[...]

The Next Chapter of Cancer Immunology Research

Jaffee EM, Ribas A. The Next Chapter of Cancer Immunology Research. Cancer Immunol Res. 2026 Jan 8;14(1):8-9. doi: 10.1158/2326-6066.CIR-25-1391. PMID: 41502310.

Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review

Hu EH. Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review. Cureus. 2025 Dec 4;17(12):e98484. doi: 10.7759/cureus.98484. PMID:[...]